FDAnews Drug Daily Bulletin

IMMTECH RECEIVES EXPANDED FUNDING COMMITMENT TO DEVELOP PAFURAMIDINE MALEATE

May 24, 2006
A A

Immtech Pharmaceuticals, Inc. announced today that it has entered agreements with the University of North Carolina Chapel Hill (UNC-Chapel Hill) to provide expanded funding and support for Immtech's development of its oral drug candidate, pafuramidine maleate (DB289), to treat African sleeping sickness (trypanosomiasis). PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-23-2006/0004367171&EDATE=)